Full Press Release Details
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
PVLA Neutral Sentiment
Gebauer M, Schiefner A, Matschiner G, Skerra A. (2013) Combinatorial design of an Anticalin directed against the extra-domain b for the specific targeting of oncofetal fibronectin
Key Takeaway: The article discusses a combinatorial design of an Anticalin aimed at targeting oncofetal fibronectin. It highlights the work of Gebauer et al. in 2013, but lacks specific details on the findings or implications of the research. The text appears to be a placeholder with no substantial content provided.
Price reaction · baseline $22.05 (2025-06-20 close) · hit pre-market · 1 other PVLA headline(s) in the window, move may be shared
day 0 close · peak
+2.2%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+106%
120-day peak, hindsight
Typical move
8.9%
average across 5 past catalysts
Cash runway
~58 mo
Minimal dilution risk
Lead asset
PTX-022
Phase 3 · Pachyonychia Congenita